Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Q4 Revenues Jump 7 Percent

NEW YORK (GenomeWeb) – Agilent Technologies said after the close of the market Monday that its fourth quarter revenues increased 7 percent year over year.

For the three months ended Oct. 31, Agilent reported revenues of $1.19 billion compared to $1.11 billion in the same quarter a year ago.  On average, analysts had expected Q4 revenues of $1.17 billion.

On a non-GAAP basis, excluding the impact of currency, divestiture costs associated with the exit of the NMR business, and other acquisitions and divestitures within the past 12 months, revenues grew 6 percent year over year.

Agilent's crosslab group grew 9 percent year over year to $404 million, with healthy growth across services and consumables and across most regions and end markets, while its diagnostics and genomics group revenues grew 9 percent to $210 million led by increasing demand for pathology products and companion diagnostics services. Meanwhile, the firm's life sciences and applied markets group grew 5 percent year over year to $575 million with strength in chemical and energy, academia and government, and food end markets.

Net income in the fourth quarter was $177 million, or $.54 per share, up from $126 million, or $.38 per share in the year-ago quarter. Excluding intangible amortization of $28 million, transformation costs of $7 million, and acquisition and integrations costs of $5 million, adjusted EPS was $.67 per share in Q4 2017, besting the Wall Street estimate of $.62 per share.

Agilent spent $89 million on R&D in the fourth quarter, up 6 percent from $84 million a year ago. The company's SG&A expenses rose 1 percent to $325 million from $321 million a year ago.

For full fiscal year 2017, Agilent posted revenues of $4.47 billion, up 6 percent from $4.20 billion in fiscal year 2016 and ahead of analysts' average estimate of $4.45 billion.

Full-year 2017 net income was $684 million, or $2.10 per share, compared to $462 million, or $1.40 per share a year ago. On a non-GAAP basis, EPS was $2.36, beating analysts' average estimate for EPS of $2.32.

Agilent's full-year R&D expenses grew 3 percent to $339 million from $329 million, while its SG&A expenses fell 2 percent to $1.23 billion from $1.25 billion.

The company finished the quarter with $2.68 billion in cash and cash equivalents.

Agilent said that it expects fiscal first quarter 2018 revenue of $1.145 billion to $1.165 billion, with non-GAAP EPS of $.55 to $.57 per share. Analysts on average are expecting Q1 revenues of $1.15 billion and adjusted EPS of $.60.

For fiscal year 2018 the company is expecting revenues of $4.72 billion to $4.74 billion and non-GAAP EPS of $2.50 to $2.56. Wall Street is expecting fiscal year 2018 revenues of $4.73 billion and adjusted EPS of $2.59.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.